Puretrig 5000 (HCG 5000iu)

Product Overview

Puretrig 5000 is a pharmaceutical formulation that contains human chorionic gonadotropin (HCG) at a strength of 5,000 international units per vial. It is supplied by Gufic Biosciences Ltd., a manufacturer with a reputation for adhering to strict quality standards in the production of injectable biologics. Each package includes a single 1 ml vial of lyophilized powder intended for reconstitution with sterile water prior to administration. The product is indicated for the treatment of female infertility associated with anovulation or oligoovulation, as well as for male hypogonadism resulting from insufficient endogenous gonadotropin secretion. Pack size options of three, six, or nine vials allow clinicians to tailor treatment regimens to individual patient needs while maintaining consistent potency throughout the course of therapy.

What is Puretrig 5000?

Puretrig 5000 refers to the specific brand and dosage form of HCG that delivers 5,000 IU of the hormone in a sterile, lyophilized format. The active ingredient, human chorionic gonadotropin, mimics the natural luteinizing hormone activity that stimulates the ovaries in women and the testes in men. In clinical practice, the medication is valued for its ability to trigger ovulation in selected infertility patients and to support testosterone production in men with documented hypogonadism. The product is classified under the category of female infertility treatments, yet its therapeutic reach extends to endocrine disorders in the male reproductive axis. Gufic Biosciences Ltd. manufactures Puretrig 5000 under a rigorous batch‑testing protocol that includes potency assays, sterility testing, and endotoxin evaluation, ensuring that each vial meets the specifications required by regulatory authorities such as the United States Pharmacopeia (USP).

Uses and Benefits

Uses and Benefits of Puretrig 5000 revolve around its role as an ovulation induction agent and a stimulant of endogenous testosterone synthesis. In women, clinicians often employ a single 5,000‑IU dose administered intramuscularly or subcutaneously after ovarian stimulation protocols, which can increase the likelihood of mature follicle development and subsequent fertilization. The hormone’s ability to synchronize follicular maturation makes it a cornerstone in assisted reproductive technologies such as in‑vitro fertilization (IVF) cycles. For men, the same dose can elevate serum testosterone levels, improve sperm count, and ameliorate symptoms associated with secondary hypogonadism. Clinical studies indexed in PubMed have demonstrated modest improvements in pregnancy rates when HCG is combined with other ovulation agents, while separate research shows enhanced gonadal function in hypogonadal males receiving regular HCG supplementation. Because the medication is derived from a naturally occurring protein, it exhibits a favorable safety profile when used according to prescribed regimens, and its relatively long half‑life permits infrequent dosing schedules.

How It Works

Mechanistically, Puretrig 5000 binds to luteinizing hormone/choriogonadotropin receptors on ovarian granulosa cells and Leydig cells. In women, this mimics the natural LH surge that finalizes oocyte maturation and triggers ovulation; the effect lasts about 36–48 hours, providing a narrow window for timed intercourse or egg retrieval. In men, receptor activation stimulates testosterone production, supporting spermatogenesis and secondary sexual characteristics. Because HCG is a protein, its activity persists longer than small‑molecule hormones, allowing a single 5,000‑IU dose to sustain hormonal stimulation. Laboratory tests typically show a rise in serum estradiol within 24 hours, confirming ovarian response. Understanding these dynamics helps clinicians time interventions and adjust adjunct medications for optimal outcomes.

Dosage Guidelines

Dosage guidelines for Puretrig 5000 are individualized based on the clinical indication, patient age, ovarian reserve, and response to prior therapy. For ovulation induction in women, a single intramuscular or subcutaneous injection of 5,000 IU is commonly administered after a period of ovarian stimulation, often on day 6 to 8 of the menstrual cycle, to trigger the luteinizing hormone surge. In some protocols, a split dose of 2,500 IU administered 24 hours apart may be used to fine‑tune follicular maturation. For male patients with hypogonadism, typical regimens involve 5,000 IU administered every 2–3 days for several weeks, with dose adjustments guided by serum testosterone measurements. Prior to each injection, the lyophilized powder must be reconstituted with a sterile diluent, and the solution should be inspected for particulate matter or discoloration. Proper storage at 2 °C–8 °C protects the protein from degradation, while handling at room temperature for brief periods is permissible if the product label permits. Clinicians are advised to document the date of reconstitution and discard any unused portion after 24 hours to maintain potency and sterility. For detailed prescribing information, refer to the FDA guidance and consult NIH resources.

Side Effects

Like all biologic medications, Puretrig 5000 can be associated with adverse effects, although most are mild and self‑limiting. The most frequently reported events include injection‑site reactions such as pain, redness, or swelling, which typically resolve within a few days. Systemic side effects may comprise headache, fatigue, and mild abdominal discomfort, reflecting transient hormonal fluctuations. In rare circumstances, patients may experience ovarian hyperstimulation syndrome (OHSS) in women, characterized by abdominal distension, shortness of breath, and rapid weight gain; prompt medical evaluation is essential in such cases. Allergic responses, although uncommon, can manifest as rash, itching, or, in severe instances, anaphylaxis, necessitating immediate discontinuation of the drug and administration of appropriate emergency measures. Because the product contains human chorionic gonadotropin derived from purified sources, the risk of contamination is minimized, yet clinicians should remain vigilant for signs of infection or unexpected laboratory abnormalities. Reporting of adverse events to local pharmacovigilance authorities helps maintain a comprehensive safety profile. For additional safety data, see MedlinePlus.

Warnings and Precautions

Warnings and precautions associated with Puretrig 5000 stress careful patient selection and monitoring. The drug is contraindicated in those with known hypersensitivity to HCG or its excipients, active malignancies, uncontrolled thyroid disease, or unresolved ovarian cysts. Pregnant individuals should not receive HCG, as it may affect fetal development. Prior to treatment, baseline labs including estradiol, testosterone, and renal function are recommended to identify conditions that could be worsened by hormonal stimulation. Ongoing ultrasound can detect excessive follicular growth, prompting dose modification to avoid ovarian hyperstimulation syndrome. Patients must report sudden weight gain, shortness of breath, or severe pelvic pain, which may signal serious complications. Store the medication in its original container, protect from light, and discard if the vial shows leakage or particles, ensuring only sterile, potent material is used.

FAQs

Q1: How should Puretrig 5000 be stored before use?
A: Store the unopened vial at 2 °C–8 °C in a refrigerator; once reconstituted, keep the solution at room temperature and use within 24 hours.

Q2: Can Puretrig 5000 be used for weight loss?
A: No, HCG is not approved for weight loss; its use for that purpose lacks scientific support and may pose health risks.

Q3: Is a prescription required to purchase Puretrig 5000?
A: Yes, federal regulations require a licensed healthcare provider’s prescription before dispensing HCG for approved indications.

Q4: What is the typical duration of treatment with Puretrig 5000?
A: Treatment length varies by indication; ovulation induction cycles often involve a single dose, while male hypogonadism regimens may span several weeks with periodic dosing.

Q5: Are there any dietary restrictions while using Puretrig 5000?
A: No specific dietary restrictions are required, but patients are advised to maintain adequate hydration and avoid excessive alcohol intake during therapy.

Related Products

• Ovidac (HCG (HUMAN CHORIONIC GONADOTROPIN))
• hCG 10000iu Injection (Human Chorionic Gonadotropin)
• hCG 5000iu Injection (Human Chorionic Gonadotropin)
• Gestobond 400 mg (Progesterone)
• Ovidac 10000 iu (HCG (Human Chorionic Gonadotropin))
• Fertigyn 10000 iu (HCG 10000iu)
• Ovidac 5000iu (HCG (Human Chorionic Gonadotropin))
• Hucog Liquid Form 10000 (HCG 10000iu)
• Hucog Liquid Form 5000 (HCG 5000iu)
• Fertigyn 5000 (HCG 5000iu)
• Hucog Liquid Form (HCG (Human Chorionic Gonadotropin))
• Fertigyn (HCG (Human Chorionic Gonadotropin))